Simulation the Alzheimer brain response to 915 nm laser irradiation: Exploring power levels, laser configurations, temperature, and dosages for effective photobiomodulation therapy

Infrared Physics & Technology, Journal Year: 2025, Volume and Issue: unknown, P. 105860 - 105860

Published: April 1, 2025

Language: Английский

---

Unraveling the Complexity of Alzheimer’s Disease: Insights into Etiology and Advancements in Treatment Strategies

Journal of Molecular Neuroscience, Journal Year: 2025, Volume and Issue: 75(2)

Published: April 25, 2025

Language: Английский

---

Sex differences in sleep apnea and Alzheimer’s Disease: role of cerebrovascular dysfunction

npj Women s Health, Journal Year: 2025, Volume and Issue: 3(1)

Published: May 5, 2025

Obstructive sleep apnea (OSA) significantly impacts cardiovascular health in post-menopausal females. Given that and cerebrovascular diseases are tightly linked, OSA-mediated on function Alzheimer's Disease (AD) risk also likely more manifest This review will: summarize sex differences function, the vascular hypothesis of AD, characterize OSA phenotype implications for control, highlight AD risk.

Language: Английский

---

Disparities in Early Lecanemab Uptake Among US Medicare Beneficiaries

JAMA Network Open, Journal Year: 2025, Volume and Issue: 8(5), P. e2511711 - e2511711

Published: May 15, 2025

This cross-sectional study examines lecanemeb update among Medicare fee-for-service beneficiaries with Alzheimer disease or mild cognitive impairment and evaluates whether there are disparities potentially eligible patients.

Language: Английский

---

Profiling aducanumab as a treatment option for alzheimer’s disease: an overview of efficacy, safety and tolerability

Expert Review of Neurotherapeutics, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 9

Published: Sept. 18, 2024

Alzheimer's disease is the most common form of dementia worldwide. Aducanumab, a monoclonal antibody targeting amyloid-beta, became first disease-modifying treatment for mild cognitive impairment due to (AD) and AD suggested that removing amyloid from brain, especially in early AD, might make difference slowing decline.

Language: Английский

---

Challenges for emergency departments: Anti‐amyloid therapy and amyloid‐related imaging abnormalities in persons with dementia

Journal of the American Geriatrics Society, Journal Year: 2024, Volume and Issue: unknown

Published: July 22, 2024

Anti-amyloid therapies (AAT) offer promise to persons with Alzheimer's dementia (AD).1, 2 The number of undergoing AAT will grow in the coming years, and many could potentially present U.S. emergency departments (ED) serious adverse treatment reactions, particularly amyloid-related imaging abnormalities (ARIA), which manifest as intracerebral edema or hemorrhage varying symptoms.3 There are currently no evidence-based clinical policies care guidelines for pre-hospital ED management ARIA, current disparities access brain neuroradiology expertise,4, 5 neurology consultation,6 may result on finding themselves at EDs without necessary expertise resources optimally manage their presentation.4-8 Consequently, they undergo unnecessary tests treatments, hospitalization, transfers another hospital. Further, potential interactions between anticoagulants thrombolytics would complicate time-sensitive acute conditions.9, 10 goal this paper was outline challenges recommend a framework development address these challenges. "There abnormalities, expertise, consultation, anti-amyloid therapy presentation." Current recommendations aducanumab lecanemab restrict use mild cognitive impairment (MCI) AD confirmed amyloid beta (Aβ) biomarkers (amyloid PET CSF Aβ).11, 12 Recent 2021 population estimates ≥65 years suggest 5.7 million Aβ+ MCI 2.45 AD.13 These projected increase by 76% 128%, respectively, 2060.14 percentage eligible is uncertain, but range from 9% 57% based rates contraindications (e.g., anticoagulant therapy, stroke/TIA/seizure within last year).15-17 Therefore, we estimate 0.72 4.6 AAT. Most attention effects has centered can either (ARIA-E) hemorrhage, most commonly microhemorrhages hemosiderin deposits (ARIA-H).8 A recent meta-analysis 19 studies pooled sample 9429 patients yielded incidence 6.5% AIRA-E 7.8% ARIA-H,18 although report published before results donanemab phase 3 trials were released, both reported higher raw proportions group participants ARIA-E (12.6%; 24.0%) ARIA-H (17.3%; 31.4%), respectively.1, ARIA be asymptomatic approximately 80% cases,3, 18 wide symptoms, including headache, confusion, dizziness (i.e., lightheadedness vertigo), seizures, visual disturbances, focal neurologic deficits, systemic viral (influenza-like) symptoms.3, 8 In trials, screening accomplished routinely scheduled MRI, additional unscheduled MRIs investigator discretion trial. One not expect symptoms indications emergent receive MRI ED. More likely, have complaints suspicious other neurological conditions. receiving presenting evaluation likely toward upper end above estimates. response triaging new challenging medical services (EMS), well outpatient primary providers urgent clinics. Given urgency symptomatic default action evaluated If first EMS, managed an stroke, given existing EMS protocol stroke.19 With lack education regarding deficit due reaction entertained early person's presentation. clinician faced three determining if patient findings alternative diagnoses: verifying that AAT, especially situations where cannot provide history. As administered infusion, available medication records information. second recognition its symptoms. third accessing utilizing optimal tools diagnosis impact Determination neuroimaging difficult resource dependent. ideal efficiently situation those 24/7 (a) recommended sequences required diagnosis,3, patient's pre-treatment comparison scanner identical assessment20; (b) neurologist and/or radiologist diagnose ARIA; (c) consulting expert ARIA.3, 6-8 level care. 2008 found only 66% had availability in-house 20% depended mobile services, it unclear facilities access.21 While since increased nationally, know verify this, revealed Minnesota,5 general,4 cerebrovascular imaging.22 Many transferred appropriate radiology resources. Some also under behavioral neuropsychiatrist who geographically distant consultation follow-up after visit. Another important concern involves any presents ischemic stroke window thrombolytic therapy. risk versus benefit agents presently patients, very limited data safety Presently, aware one case treated t-PA received doses subsequently diagnosed multiple cerebral hemorrhages, etiologic factor hemorrhage.10, 23 scenarios anti-platelet anticoagulation such pulmonary embolism cardiovascular event. research needed situations. However, decision administer types medications fall treating physician familiar risks better Despite uncertainties estimates, must prepare possibility increasing visits possible reactions. testing hospitalizations, hospital transfers, all associated outcomes among older dementia.24-27 For individuals whose etiologies, long wait times chaotic environment trying experience dementia.28 Even when consultants available, work up almost certainly length stay delirium events, hospitalization facilitate consult carries similar risks.24, 26 Risks underestimated racial minorities, low representation aducanumab, trials.29 Ultimately, dynamic, numerous complex implications evolve over time. Interdisciplinary guidance partnerships critical facing landscape ahead. AXL REK responsible concept design manuscript. RDS ASR contributed original material. All authors preparation revision reviewed manuscript approved submission JAGS. conflicts interest. supported R01 AG037561 (as PI) 1P20AG068024 co-I). study sponsors role design; collection, analysis interpretation data; writing report; submit publication. presented does reflect respective official individual funding organizations.

Language: Английский

---

Modeling the Population Equity of Alzheimer Disease Treatments in the US

JAMA Network Open, Journal Year: 2024, Volume and Issue: 7(10), P. e2442353 - e2442353

Published: Oct. 31, 2024

The arrival of new medications for Alzheimer disease (AD) has prompted efforts to measure their value using conventional cost-effectiveness analyses; however, these analyses focus on how much health improvement generate per dollar spent. As AD disproportionately affects older adults, women, racial and ethnic minority individuals, individuals with lower socioeconomic educational levels, it is critical also examine the equity outcomes treatment.

Language: Английский

---

Association of Religious Service Attendance and Neuropsychiatric Symptoms, Cognitive Function, and Sleep Disturbances in All-Cause Dementia

International Journal of Environmental Research and Public Health, Journal Year: 2023, Volume and Issue: 20(5), P. 4300 - 4300

Published: Feb. 28, 2023

Commonly reported in dementia, neuropsychiatric symptoms (NPS), cognitive decline, and sleep disturbances indicate dementia progression. With the growing burden, identifying protective factors that may slow progression is increasingly essential. Religion spirituality are associated with better mental physical health, yet few studies have been older adults dementia. This study examines associations between religious service attendance of Using data from Health Retirement Study 2000, 2006, 2008 sub-study, Aging, Demographics, Memory 2001–2003, 2006–2007, 2008–2009, we examined association symptoms, function, among U.S. aged 70 years all-cause (N = 72) using Spearman’s partial Rho correlation controlling for social interaction. Significant were identified NPS (rs (97) –0.124, 95% CI [–0.129, –0.119], p < 0.0005); rs –0.018, [–0.023, –0.013], 0.001); disturbances, –0.275, [–0.280, –0.271], 0.0005). Beyond adjusting interaction, increased was lower NPS, fewer disturbances. Clinical trials longitudinal a larger sample size examining religion warranted.

Language: Английский

---

The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research

Alzheimer s & Dementia Translational Research & Clinical Interventions, Journal Year: 2023, Volume and Issue: 9(3)

Published: July 1, 2023

In the asymptomatic "preclinical" phase of Alzheimer's disease (AD), abnormal biomarkers indicate risk for developing cognitive impairment. Biomarker information is increasingly being disclosed to participants in research settings, and biomarker testing results disclosure will be implemented clinical settings future. has potential psychosocial benefits harms, impacting affected individuals their support person(s). Limited data are available about with whom share results, that necessary develop protocols post-disclosure resources. Additionally, existing been conducted largely White cohorts, limiting applicability future populations.

Language: Английский

---

Introduction to Alzheimer's Disease, Biomarkers, and the AI Revolution

Advances in medical technologies and clinical practice book series, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 23

Published: June 28, 2024

Alzheimer's disease (AD) is a progressive neurodegenerative that results in steady decline cognitive ability and memory function. As society ages, the need for an optimum AD management strategy becomes more important. This chapter analyzes stage-construction etiology escalating symptoms of discovered throughout this review, as well identification barrier to precise diagnosis. The artificial intelligence achieve quicker detection through machine learning, data analytics, predictive modeling also being considered. Therefore, employing AI AD-related studies novel approach enhancing patient outcomes. Proper diagnosis parallel increased probability many parameters one most difficult moments identify. However, use evaluation sensor network technologies big analysis has advanced, preventive instruments can be used. Thus, technology gives humanity hope stop or, at very least, slow down tragedy.

Language: Английский

---